EUVIMEDEUVIMED entdecken
Crossref

Maraviroc alleviates neuropathic pain symptoms in a mouse model of spared nerve injury

Wei Zhao, Cigdem Sevim Bayrak, Fiona Chen, Hsiao-Yun Lin, Bin Zhang, Jun Wang

Molecular Pharmacology · 2026-05 · 108 (5-6) · 100126

DOI: 10.1016/j.molpha.2026.100126 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecular Pharmacology, 2026-05. Verfasst von Wei Zhao und 5 weiteren Autor:innen. Beteiligte Einrichtung: Spinal Cord Damage Research Center, James J. Peters Veteran Affairs Medical Center, Bronx, New York; Department of Medicine, Icahn School of Medicine…. Hauptthemen laut MEDLINE: Maraviroc, Neuralgia, CCR5 Receptor Antagonists, Peripheral Nerve Injuries. Die Arbeit nennt 62 Literaturangaben. Gefördert von: RRD VA, US Department of Veterans Affairs.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Chronic pain represents a major health problem in the health care system. According to the CDC data brief in 2020, 20.4% of adults have chronic pain. There has been no promising therapy for chronic pain. Currently available treatments include medications such as nonsteroidal anti-inflammatory drugs, antiepileptic drugs, tricyclic antidepressants, corticosteroids, opioids, and cannabinoids, all of which may cause various negative side effects. Thus, there is an urgent need to develop novel, efficacious, and safe interventions for treating pain. Studies have shown that proinflammatory cytokines and chemokines make important contributions to the initiation and persistence of pain. We have found that C-C motif chemokine ligand 5 levels increased at day 14 post-spared nerve injury (SNI). This study was designed to investigate the effect of maraviroc (MVC), an FDA-approved CCR5 antagonist, on neuropathic pain in a mouse model of SNI. We found that MVC alleviated SNI-induced mechanical allodynia at 3, 7, and 14 days postinjury. MVC treatment also prevented SNI-mediated thermal hypersensitivity at 7 and 14 days postinjury in both male and female cohorts. SNI resulted in weight-bearing deficits, which were corrected by MVC administration in male mice. RNA sequencing analysis revealed that MVC rescued SNI-induced dysregulation of sex-specific canonical pathways in the spinal cord. Collectively, our findings showed that MVC could reduce neuropathic pain following peripheral nerve injury, providing a base for the repurposing of this FDA-approved human immunodeficiency virus drug as a pain reducer in clinical applications. SIGNIFICANCE STATEMENT: Spared nerve injury-induced neuropathic pain is associated with upregulation of the C-C motif chemokine ligand 5. Targeting the C-C motif chemokine ligand 5-CCR5 axis with FDA-approved maraviroc alleviated pain phenotype through modulating different pathways in male and female mice.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MaravirocNeuralgiaCCR5 Receptor AntagonistsPeripheral Nerve InjuriesAnimalsMaleFemaleMiceDisease Models, AnimalMice, Inbred C57BLHyperalgesiaReceptors, CCR5

Stichwörter der Autor:innen

CCL5CCR5HypersensitivityMaravirocNeuropathic pain

Substanzen

MaravirocCCR5 Receptor AntagonistsReceptors, CCR5

Autor:innen und Institutionen

  • Spinal Cord Damage Research Center, James J. Peters Veteran Affairs Medical Center, Bronx, New York; Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, New York. Electronic address: wei.zhao@mssm…
  • Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, New York.
  • Department of Neurology, Icahn School of Medicine at Mount Sinai, New York, New York.
  • Department of Neurology, Icahn School of Medicine at Mount Sinai, New York, New York; Research & Development, James J. Peters Veteran Affairs Medical Center, Bronx, New York.
  • Department of Neurology, Icahn School of Medicine at Mount Sinai, New York, New York; Research & Development, James J. Peters Veteran Affairs Medical Center, Bronx, New York. Electronic address: jun.wang@mssm.edu.

Förderung

  • RRD VA
  • US Department of Veterans Affairs

Zitieren

APA

Zhao, W., Sevim Bayrak, C., Chen, F., Lin, H. Y., Zhang, B., & Wang, J. (2026). Maraviroc alleviates neuropathic pain symptoms in a mouse model of spared nerve injury. Molecular Pharmacology, 108(5-6), 100126. https://doi.org/10.1016/j.molpha.2026.100126

Vancouver

Zhao W, Sevim Bayrak C, Chen F, Lin HY, Zhang B, Wang J. Maraviroc alleviates neuropathic pain symptoms in a mouse model of spared nerve injury. Molecular Pharmacology. 2026;108(5-6):100126. doi:10.1016/j.molpha.2026.100126

BibTeX
@article{Zhao2026,
  author = {Zhao, Wei and Sevim Bayrak, Cigdem and Chen, Fiona and Lin, Hsiao-Yun and Zhang, Bin and Wang, Jun},
  title = {Maraviroc alleviates neuropathic pain symptoms in a mouse model of spared nerve injury},
  journal = {Molecular Pharmacology},
  year = {2026},
  volume = {108},
  number = {5-6},
  pages = {100126},
  doi = {10.1016/j.molpha.2026.100126}
}
Kostenlos starten →